The new england journal of medicine
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder, M.D., Vladimir Makarov, M.D., Taha Merghoub, Ph.D., Jianda Yuan, M.D., Ph.D., Jesse M. Zaretsky, B.S., Alexis Desrichard, Ph.D., Logan A. Walsh, Ph.D., Michael A. Postow, M.D., Phillip Wong, Ph.D., Teresa S. Ho, B.S., Travis J. Hollmann, M.D., Ph.D., Cameron Bruggeman, M.A.,
Kasthuri Kannan, Ph.D., Yanyun Li, M.D., Ph.D., Ceyhan Elipenahli, B.S., Cailian Liu, M.D., Christopher T. Harbison, Ph.D., Lisu Wang, M.D.,
Antoni Ribas, M.D., Ph.D., Jedd D. Wolchok, M.D., Ph.D.,
and Timothy A. Chan, M.D., Ph.D.
ABSTRACT
Background
From the Department of Medicine (A.S., T.M., M.A.P., J.D.W.), Human Oncology and Pathogenesis Program (A.S., V.M., A.D., L.A.W., K.K., T.A.C.), Swim across America–Ludwig Collaborative Research Laboratory (T.M., Y.L., C.E., C.L., J.D.W.), Department of Radiation Oncology (T.A.C.), Department of Pathology (T.J.H.), and Immunology Program, Lud-wig Center for Cancer Immunotherapy (J.Y., P.W., T.S.H., J.D.W.), Memorial Sloan Kettering Cancer Center; Weill Cor-nell Medical College (A.S., M.A.P., J.D.W., T.A.C.); and Department of Mathemat-ics, Columbia University (C.B.) — all in New York; the Department of Molecular and Medical Pharmacology (J.M.Z., A.R.) and the Department of Medicine, Divi-sion of Hematology–Oncology, Jonsson Comprehensive Cancer Center (A.R.), University of California, Los Angeles, Los Angeles; and Bristol-Myers Squibb, Princeton, NJ (C.T.H., L.W.). Address re-print requests to Dr. Chan at the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave., Box 20, New York, NY 10065, or at chant@mskcc.org; or to Dr. Wolchok at the Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, or at wolchokj@mskcc.org.Drs. Snyder, Makarov, Merghoub, and Yuan and Drs. Wolchok and Chan contributed equally to this article.
This article was published on November 19, 2014, and updated on November 21, 2014, at NEJM.org.
DOI: 10.1056/NEJMoa1406498
Copyright © 2014 Massachusetts Medical Society.
Immune checkpoint inhibitors are effective cancer treatments, but molecular deter-minants of clinical benefit are unknown. Ipilimumab and tremelimumab are anti-bodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti–CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells.
Methods
We obtained tumor tissue from patients with melanoma who were treated with ipilimumab or tremelimumab. Whole-exome sequencing was performed on tumors and matched blood samples. Somatic mutations and candidate neoantigens gener-ated from these mutations were characterized. Neoantigen peptides were tested for the ability to activate lymphocytes from ipilimumab-treated patients.
Results
Malignant melanoma exomes from 64 patients treated with CTLA-4 blockade were characterized with the use of massively parallel sequencing. A discovery set con-sisted of 11 patients who derived a long-term clinical benefit and 14 patients who derived a minimal benefit or no benefit. Mutational load was associated with the degree of clinical benefit (P = 0.01) but alone was not sufficient to predict benefit. Using genomewide somatic neoepitope analysis and patient-specific HLA typing, we identified candidate tumor neoantigens for each patient. We elucidated a neo-antigen landscape that is specifically present in tumors with a strong response to CTLA-4 blockade. We validated this signature in a second set of 39 patients with melanoma who were treated with anti–CTLA-4 antibodies. Predicted neoantigens activated T cells from the patients treated with ipilimumab.
Conclusions
These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti–CTLA-4 agents are being considered. (Funded by the Frederick Adler Fund and others.)
n engl j med nejm.org
1

[43] attributed this hindered immune response to ...Antibody-mediated blockade of PDL1 but not PD-L...Genetic progress towards the molecular basis of ...
genetic and epigenetic changes found in all ...clinical data show that antibody blockade of these...patients with melanoma achieved a complete response...
[43] attributed this hindered immune response to ...Antibody-mediated blockade of PDL1 but not PD-L...Genetic progress towards the molecular basis of ...
热门文档